ZHANG Tiantai
Principal Investigator
Dr. Tiantai Zhang is currently the PI in the Institute of Materia Medica, CAMS & PUMC. He received his BA degree in 1993 from the School of Public Health Lanzhou University and his master degree in 1998 from the First Hospital of Lanzhou University. He obtained a Ph.D. degree from China Pharmaceutical University (2003). He then carried out postdoctoral research at the Institute of Materia Medica, CAMS & PUMC (2003-2006), focusing on the high-throughput drug screening. Zhang's research interests are mainly focused on the mechanism underlying immunity-mediated inflammatory and autoimmune disease, researching and developing novel drugs for inflammatory or autoimmune disease. So far, he has published over 60 peer-reviewed papers in the international journals such as Pharmacol. Ther., J. Neuroinflammation, Br. J. Pharmacol., Acta Pharmaceut. Sin. B, Org. Lett., etc.
He is interested in the following research projects.
1. Cellular and molecular mechanisms of inflammation-related autoimmune diseases and novel therapeutic strategies.
2. Identification of novel small molecule inhibitors targeting Janus kinase.
3. Pharmacological evaluation of active natural products and new drug discovery.
1. Therapeutic potential of NLRP3 inflammasome in multiple sclerosis. Pharmacol Ther . 2021, 227: 107880.
2. Divanillyl sulfone suppresses NLRP3 inflammasome activation via inducing mitophagy to ameliorate chronic neuropathic pain in mice. J Neuroinflammation. 2021, 18:142.
3. Emerging small-molecule inhibitors of the Bruton’s Tyrosine Kinase (BTK): current development. Eur J Med Chem . 2021, 217: 113329.
4. Exploring a novel triptolide derivative possess anti-colitis effect via regulating T cell differentiation. Int Immunopharmacol . 2021, 94:107472.
5. Aconapelsulfonines A and B, seco C20-diterpenoid alkaloids deriving via Criegee rearrangements of napelline skeleton from Aconitum carmichaelii. Chin Chem Lett . 2021, 32:33-36.
6. Methotrexate enhances antigen presentation and maturation of tumor antigens loaded DCs through NLRP3 inflammasome activation and with potentials for DC-based cancer vaccine. Ther Adv Med Oncol . 2021, 13: 1758835920987056.
7. Structure, property, biogenesis, and activity of diterpenoid alkaloids containing a sulfonic acid group from Aconitum carmichaelii. Acta Pharmaceut Sin B . 2020, 10(10):1954-1965.
8. Isotalatizidine, a C19-diterpenoid alkaloid, attenuates chronic neuropathic pain through stimulating ERK/CREB signaling pathway mediated microglial dynorphin A expression. J Neuroinflamm . 2020, 17: 13.
9. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors. Eur J Med Chem . 2020, 191:112148.
10. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of Rheumatoid arthritis. Bioorg Chem . 2020, 98: 103720.
11. A novel triptolide derivative ZT01 exerts anti-inflammatory effects by targeting TAK1 to prevent macrophage polarization into pro-inflammatory phenotype. Biomed Pharmacother . 2020, 126: 110084.
12. Design, synthesis, and evaluation of novel isoflavone derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem . 2019, 168: 207-220.
13. Aconicarmisulfonines A and B, analgesic zwitterionic C20-Diterpenoid alkaloids with a rearranged atisane skeleton from Aconitum carmichaelii. Org lett . 2019, 21 (17):6850-6854.
14. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms. J Exp Clin Cancer Res . 2019, 38(2): 49.
15. C19-Diterpenoid alkaloid arabinosides from an aqueous extract of the lateral root of Aconitum carmichaelii and their analgesic activities. Acta Pharmaceut Sin B . 2018, 8(3): 409-419.
